Trials / Unknown
UnknownNCT04303962
Efficacy of Intravenous Gamma Globulin on Guillain-Barre Syndrome
An Observational Cohort Study on the Efficacy of Intravenous Gamma Globulin on Guillain-Barre Syndrome
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Ning Wang, MD., PhD. · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Guillain-barre syndrome (GBS) is an acute immune-mediated polyneuropathy. Intravenous Gamma globulin is an effective therapy.Although high doses of gamma globulin are clinically effective, the patient's recovery and clinical prognosis vary. The establishment of a cohort study on the therapeutic effect of gamma globulin in Guillain-barre Syndrome is beneficial to the diagnosis of the disease and to the understanding of the natural course of the disease and the efficacy of drug treatment.
Conditions
Timeline
- Start date
- 2020-04-27
- Primary completion
- 2024-01-21
- Completion
- 2025-01-21
- First posted
- 2020-03-11
- Last updated
- 2022-01-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04303962. Inclusion in this directory is not an endorsement.